| Literature DB >> 34127541 |
Pablo Lamelas1,2, Martin Alberto Ragusa3,4, Rodrigo Bagur5, Iqbal Jaffer6, Henrique Ribeiro7, Adrian Baranchuk8, Fernando Wyss9, Alvaro Sosa Liprandi10, Gabriel Olivares11, Magaly Arrais12, Juan Camilo Rendon13, Jorge Catrip14, Carla Agatiello15, Fernando Cura16, Alfaro Marchena17, Fabio Sandoli de Brito18, José A Mangione19, Aníbal Damonte20, Omar Santaera21, Pedro Hidalgo22, Robby Nieuwlaat23, Ariel Izcovich3.
Abstract
In elderly (75 years or older) patients living in Latin America with severe symptomatic aortic stenosis candidates for transfemoral approach, the panel suggests the use of transcatheter aortic valve implant (TAVI) over surgical aortic valve replacement (SAVR). This is a conditional recommendation, based on moderate certainty in the evidence (⨁⨁⨁Ο).This recommendation does not apply to patients in which there is a standard of care, like TAVI for patients at very high risk for cardiac surgery or inoperable patients, or SAVR for non-elderly patients (eg, under 65 years old) at low risk for cardiac surgery. The suggested age threshold of 75 years old is based on judgement of limited available literature and should be used as a guide rather than a determinant threshold.The conditional nature of this recommendation means that the majority of patients in this situation would want a transfemoral TAVI over SAVR, but some may prefer SAVR. For clinicians, this means that they must be familiar with the evidence supporting this recommendation and help each patient to arrive at a management decision integrating a multidisciplinary team discussion (Heart Team), patient's values and preferences through shared decision-making, and available resources. Policymakers will require substantial debate and the involvement of various stakeholders to implement this recommendation. © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.Entities:
Keywords: aortic valve stenosis; heart valve prosthesis implantation; transcatheter aortic valve replacement
Mesh:
Year: 2021 PMID: 34127541 DOI: 10.1136/heartjnl-2021-319489
Source DB: PubMed Journal: Heart ISSN: 1355-6037 Impact factor: 5.994